Clinical Scorecard: SGLT2 Inhibitor Therapy Enhances Myocardial Strain and Diastolic Function in Patients with HFpEF: A Retrospective Analysis Linking Functional Improvement to Decreased Myocardial Fibrosis

At a Glance

Key Highlights

• SGLT2i treatment improved left ventricular global longitudinal strain (GLS) significantly after 6 months.
• NT-proBNP, PⅢNP, and GDF-15 levels decreased significantly in the SGLT2i group.
• Heart failure rehospitalization rate was significantly lower in the SGLT2i group compared to the control group.
• SGLT2i treatment was identified as an independent predictor of GLS improvement.
• Myocardial fibrosis markers were closely linked to the observed clinical improvements.

Guideline-Based Recommendations

Diagnosis

• Evaluate patients with HFpEF using echocardiographic parameters and serum biomarkers.

Management

• Consider long-term SGLT2i treatment for patients with HFpEF to improve myocardial strain and diastolic function.

Monitoring & Follow-up

• Monitor changes in GLS and serum fibrosis markers during follow-up.

Risks

• Assess the risk of heart failure rehospitalization in patients with HFpEF.

Patient & Prescribing Data

Patients diagnosed with HFpEF

Long-term SGLT2i therapy (≥6 months) is associated with significant clinical benefits.

Clinical Best Practices

• Utilize serum biomarkers like NT-proBNP and PⅢNP for monitoring treatment response.
• Implement a multidisciplinary approach in managing HFpEF patients.

Related Resources & Content

• SGLT2 Inhibitors in Heart Failure